Trials for Low-dose Steroid Treatment prove effective for Bone Marrow CancerIn a clinical trial that was conducted by the Eastern Cooperative Oncology Group (ECOG) and sponsored by the National Cancer Institute (NCI) and part of the National Institutes of Health, it was revealed that a low dosage regimen of steroids can prove to be an excellent option for treating bone marrow cancer patients rather than persisting for the standard dose of dexamethasone.

The trial revealed that low doses of dexamethasone, a steroid, with lenalidomide can work wonders on patients who are fighting against newly diagnosed multiple myeloma. It was also revealed that the combination of dexamethasone and lenalidomide brought fewer side-effects.

As per noted study chair Vincent Rajkumar, the combination of lenalidomide plus low-dose dexamethasone is extremely positive and truly represents a potential step ahead for treating multiple myeloma.